CRISPR is important because it made editing DNA fast, cheap, and precise enough to move gene editing from a niche laboratory technique into a practical tool for medicine, agriculture, and disease control. In December 2023, the FDA approved the first CRISPR-based therapy for sickle cell disease, and the technology is now being applied to cancer treatment, organ transplantation, crop engineering, and even efforts to eliminate malaria. No previous gene-editing method came close to this range of real-world impact this quickly.
How CRISPR Actually Works
CRISPR uses a protein called Cas9 that acts like molecular scissors, guided to a specific spot on DNA by a short piece of RNA. That guide RNA is designed to match a 20-letter stretch of the target gene. When the guide RNA finds its match, Cas9 locks on and cuts both strands of the DNA at that precise location. The cell then repairs the break, and scientists can use that repair process to disable a gene, fix a mutation, or insert new genetic material.
One crucial detail: Cas9 won’t cut just anywhere. It also needs to recognize a short signal sequence right next to the target site, called a PAM. This two-step recognition system (matching the guide RNA and finding the PAM) is what gives CRISPR its accuracy. The whole system was originally part of how bacteria defend themselves against viruses, repurposed by scientists into the most versatile gene-editing tool ever developed.
Why Older Gene-Editing Tools Couldn’t Keep Up
Before CRISPR, researchers had two main options for editing genes: zinc finger nucleases (ZFNs) and TALENs. Both worked by attaching a DNA-cutting enzyme to a protein engineered to recognize a specific gene sequence. The problem was building those recognition proteins. Each new target required designing and testing an entirely new protein from scratch, a process involving multiple rounds of bacterial transformation, plasmid purification, and digestion and ligation reactions. Generating ZFNs with high specificity had limited success even after all that work.
CRISPR changed the equation by replacing the custom protein with a simple RNA sequence. To target a new gene, you just design a new 20-letter RNA guide, which takes days instead of weeks or months. This made gene editing accessible to virtually any molecular biology lab in the world, not just a handful of highly specialized groups. The throughput, the cost, and the barrier to entry all dropped dramatically, which is why CRISPR adoption exploded across nearly every branch of biology within just a few years of its development.
The First Approved CRISPR Medicine
On December 8, 2023, the FDA approved Casgevy (exagamglogene autotemcel) for patients 12 and older with sickle cell disease who experience recurrent pain crises. It was the first FDA-approved treatment to use CRISPR/Cas9 technology. The therapy works by editing a patient’s own blood stem cells to reactivate production of fetal hemoglobin, a form of hemoglobin that prevents red blood cells from sickling.
The clinical trial results were striking. Of 30 patients with enough follow-up time to be evaluated, 29 (97%) were free from pain crises for at least 12 consecutive months after treatment. For a disease that causes episodes of debilitating pain, organ damage, and shortened life expectancy, this represented a near-complete elimination of the defining symptom.
Treating Inherited Blindness
CRISPR is also being used directly inside the body to treat conditions that can’t be addressed by editing cells in a lab dish. The BRILLIANCE trial tested a therapy called EDIT-101 for Leber congenital amaurosis type 10, a rare inherited form of blindness. The treatment was injected directly into the eye, where it edited retinal cells to correct the genetic defect causing vision loss.
About 79% of the 14 participants experienced measurable improvement in vision, with 11 out of 14 reporting gains in both vision and quality of life. The therapy showed no dose-limiting toxicities. This trial was significant not just for its results but for what it proved: CRISPR could be delivered into living tissue and work safely without removing cells from the body first.
Making Cancer Immunotherapy More Effective
One of CRISPR’s most promising applications is improving cancer treatment. CAR-T cell therapy, where a patient’s immune cells are engineered to recognize and attack tumors, has shown remarkable results in blood cancers but struggles with solid tumors. CRISPR is being used to solve several of the problems that limit CAR-T effectiveness.
Researchers are using CRISPR to knock out genes that act as “off switches” on T-cells. Tumors exploit these switches, particularly proteins called PD-1 and CTLA-4, to shut down the immune response. In preclinical studies, deleting PD-1 from CAR-T cells enhanced their long-term persistence and activity, while deleting CTLA-4 improved their ability to multiply and stay active. Clinical trials are now testing these edited cells in patients with solid tumors.
CRISPR also enables the creation of “universal” CAR-T cells. Current CAR-T therapy requires engineering each patient’s own immune cells, a process that’s expensive and time-consuming. By using CRISPR to remove the molecules that cause immune rejection, researchers can create off-the-shelf CAR-T cells from a single donor that could treat many patients.
Pig Organs Edited for Human Transplant
More than 100,000 people in the U.S. are waiting for organ transplants, and thousands die each year before one becomes available. CRISPR has made xenotransplantation, using animal organs in humans, closer to reality than at any point in medical history. The company eGenesis has produced pigs with 69 genetic edits designed to make their kidneys compatible with human biology.
Ten of those edits directly address the rejection problem. Three genes responsible for producing sugar molecules that trigger the human immune system are knocked out. Seven human genes are added: two that regulate the complement system (part of the immune response that would otherwise destroy a foreign organ), two that prevent microscopic blood clots, one that reduces inflammation, and two others that help the organ coexist with the human immune system. A CRISPR-edited pig kidney recently functioned in a human recipient for 271 days before being removed. In China, a patient receiving a kidney from a 6-gene-edited pig has survived more than eight months with the organ still functioning.
Engineering Crops for a Changing Climate
CRISPR’s importance extends well beyond medicine. As climate change intensifies droughts and reduces arable land, researchers are using CRISPR to develop crops that can tolerate harsher conditions. In maize, editing a gene called ARGOS8 produced plants that showed substantially improved grain production under drought conditions with zero yield loss under normal growing conditions. That’s a critical feature: the edit helps during drought without costing anything during good years.
In rice, multiple CRISPR targets are being explored to improve tolerance to drought and other stresses. Tomatoes have been edited to produce larger fruits under stress conditions, extend shelf life without affecting firmness or plant growth, and even change color by modifying pigment genes. High-amylose wheat, which has more resistant starch and potential health benefits, has been developed through CRISPR editing of starch-branching enzyme genes. Unlike traditional genetic modification that inserts foreign DNA, many CRISPR edits simply tweak existing genes, which has simplified regulatory pathways in several countries.
Gene Drives Against Malaria
Perhaps the most ambitious use of CRISPR is the development of gene drives to combat malaria, which still kills over 600,000 people annually. A gene drive is a genetic element that spreads itself through a population faster than normal inheritance would allow. Using CRISPR, researchers have engineered mosquitoes that carry genes producing antimicrobial proteins which block the malaria parasite from developing inside them. The gene drive component ensures these modifications spread through wild mosquito populations over generations.
A recent study in Tanzania generated a transgenic strain of the primary African malaria mosquito that robustly inhibited genetically diverse malaria parasites obtained from naturally infected children, not just lab strains. The research team designed the system with a modular safety approach, separating the parasite-blocking function from the gene drive component. This allows rigorous risk assessment and community engagement before any self-propagating elements are introduced into the wild.
What’s Moving Through Clinical Trials
The pipeline of CRISPR-based therapies is expanding rapidly. Intellia Therapeutics is running two global Phase 3 trials for a CRISPR treatment targeting hereditary transthyretin amyloidosis, a progressive disease where misfolded proteins damage the heart and nerves. One trial focuses on patients with heart disease and aims to enroll at least 500 participants. The other targets nerve damage. A separate Intellia program dosed its first Phase 3 participant in January 2025, with a goal of commercial availability by 2027.
The World Health Organization has published a governance framework addressing the ethical boundaries of genome editing, distinguishing between somatic editing (which affects only the treated patient) and germline editing (which would be passed to future generations). Somatic therapies like Casgevy are moving forward with broad international support. Germline editing in humans remains effectively off-limits under current guidelines, with the WHO recommending robust oversight and flagging concerns about clinics in countries with minimal regulation offering heritable editing services.